Kieron Dunleavy, MD
Medical Oncology · Washington, DCNPI 1154610467
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $113,616 of the $139,172 with a category attached, or 81.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 16.1%. Reporting peaked in 2023 at $32,530 and has fallen 55.6% since, to $14,455 in 2025.
Across 121 payments — averaging $1150.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$22K
- Chugai Pharmaceutical Co., Ltd.$20K
- Beigene USA, Inc.$14K
- AstraZeneca$13K
- Janssen Research & Development, LLC$12K
- AbbVie$9K
- plus $50K from 25 others
Across 52 payments — averaging $24,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$606K
- Pharmacyclics LLC, An Abbvie Company$328K
- Genentech, Inc.$180K
- Gilead$61K
- Acerta Pharma LLC$40K
- Bristol Myers Squibb$27K
- plus $12K from 3 others
What the payments were for
- Consulting fees$113,61682%
- Speaking & faculty fees$2,2952%
- Travel & lodging$19,40614%
- Food & beverage$3,7903%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 16 | $22,349 |
| Chugai Pharmaceutical Co., Ltd. | 4 | $19,857 |
| Beigene USA, Inc. | 6 | $13,872 |
| AstraZeneca | 17 | $13,111 |
| Janssen Research & Development, LLC | 9 | $11,606 |
| AbbVie | 12 | $8,591 |
| Amgen | 6 | $8,512 |
| Gilead | 3 | $6,770 |
| Janssen Scientific Affairs, LLC | 5 | $6,463 |
| Incyte Corporation | 5 | $6,119 |
| Daiichi Sankyo Inc. | 3 | $4,489 |
| Acrotech Biopharma Inc. | 5 | $4,477 |
| Genentech USA, Inc. | 3 | $2,809 |
| Genentech, Inc. | 1 | $2,310 |
| Karyopharm Therapeutics Inc. | 1 | $2,295 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,076 |
| Morphosys, US Inc. | 1 | $1,150 |
| Bayer | 1 | $900 |
| National Marrow Donor Program | 2 | $345 |
| Seagen Inc. | 3 | $343 |
| Pfizer | 4 | $248 |
| Verastem, Inc. | 1 | $94 |
| Beone Medicines USA, Inc. | 3 | $78 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $65 |
| Johnson & Johnson | 2 | $51 |
| Stemline Therapeutics Inc. | 1 | $45 |
| Tersera Therapeutics LLC | 1 | $35 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,172 in reported general payments places this provider in the 85th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 36 | $598,480 |
| ImbruvicaIbrutinib | 16 | $458,142 |
| BrukinsaZanubrutinib | 20 | $288,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $13,111 | $598,48036 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $65 | $458,14216 claims |
| Beigene USA, Inc.Brukinsa | $13,872 | $288,31520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 medical oncology providers in District of Columbia.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Joshua ReussWashington$218K
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Asim AminWashington$120K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
- Kimberley DoucetteWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.